|
Antinuclear antibody detection during adalimumab treatment |
||||
| Treatment |
Week |
Number of positive ANA sera (%) |
||
|
|
||||
| ANA |
Anti-dsDNA |
Anti-ENA |
||
|
|
||||
| Adalimumab (n = 57) |
0 |
4 (7) |
0 (0) |
3 (5.2) |
| 24 |
9 (16) |
2 (3.5) |
0 |
|
| 48 |
12 (21) |
4 (7) |
2 (3.5) |
|
| Total |
16 (28) |
4 (7) |
5 (9) |
|
| P |
<0.01 |
<0.05 |
n.s. |
|
| Control RA (n = 55) |
0 |
5 (9) |
0 |
4 (7) |
| 24 |
2 (3.5) |
0 |
0 |
|
| 48 |
3 (5.2) |
0 |
1 (1.7) |
|
| Total |
8 (14.5) |
0 (0) |
5 (8.7) |
|
| P |
n.s. |
n.s. |
||
|
ANA, antinuclear antibodies; anti-dsDNA, anti-double-stranded DNA autoantibodies; ENA, extractable nuclear antigens; n.s., not significant; RA, rheumatoid arthritis. | ||||
Atzeni et al. Arthritis Research & Therapy 2006 8:R3 doi:10.1186/ar1851 |
||||